Maxpro Capital Acquisition Corp. Cl A (JMAC) News
Filter JMAC News Items
JMAC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JMAC News Highlights
- For JMAC, its 30 day story count is now at 2.
- Over the past 3 days, the trend for JMAC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MP are the most mentioned tickers in articles about JMAC.
Latest JMAC News From Around the Web
Below are the latest news stories about MAXPRO CAPITAL ACQUISITION CORP that investors may wish to consider to help them evaluate JMAC as an investment opportunity.
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business CombinationTaipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”) and Apollomics Inc. (“Apollomics”), deposited additional payments in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the “Extension Payment”) into the Company’s trust account for its public stockholders. This deposit enables the Company to extend the date by which the Co |
Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business CombinationTAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to consummate a business combination from January 13, 2023 to April 13, 2023 (the “Extension”). The Extension is the second of two three-month extensions permitted under the Company’s governing documents. In connection with |
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor AberrationsFOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. The FDA granted the Orphan Drug Designation in August. “While NSCLC |
Maxpro Capital Acquisition extends it deadline to complete business combinationMaxpro Capital Acquisition (JMAC) has announced that its sponsor, MP One Investment, has requested to extend the date by which the Co. has to consummate a business combination from Oct |
Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs –Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined $11 billion non-small cell lung cancer (“NSCLC”) and acute myeloid leukemia (“AML”) market opportunity –Transaction proceeds to accelerate development of late-stage |